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CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative
Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls
from 10 Studies
The CHEK2 Breast Cancer Case-Control Consortium*
Previous studies of families with multiple cases of breast cancer have indicated that a frameshift alteration in the
CHEK2 gene, 1100delC, is associated with an elevated frequency of breast cancer in such families, but the risk
associated with the variant in other situations is uncertain. To evaluate the breast cancer risk associated with this
variant, 10,860 breast cancer cases and 9,065 controls from 10 case-control studies in ﬁve countries were genotyped.
CHEK2*1100delC was found in 201 cases (1.9%) and 64 controls (0.7%) (estimated odds ratio 2.34; 95% CI
1.72–3.20; ). There was some evidence of a higher prevalence of CHEK2*1100delC among casesPp .0000001
with a ﬁrst-degree relative affected with breast cancer (odds ratio 1.44; 95% CI 0.93–2.23; ) and of aPp .10
trend for a higher breast cancer odds ratio at younger ages at diagnosis ( ). These results conﬁrm thatPp .002
CHEK2*1100delC confers an increased risk of breast cancer and that this risk is apparent in women unselected
for family history. The results are consistent with the hypothesis that CHEK2*1100delC multiplies the risks as-
sociated with susceptibility alleles in other genes to increase the risk of breast cancer.
Introduction
CHEK2 (MIM 604373) encodes a G2 checkpoint kinase
that plays a critical role in DNA damage repair. It is the
human orthologue of the yeast Cds1 and Rad53 G2
checkpoint kinases (Matsuoka et al. 1998). Activation
of these proteins in response to DNA damage prevents
cellular entry into mitosis. In mammalian cells, activa-
tion of CHEK2 in response to ionizing radiation is reg-
ulated through phosphorylation by ataxia telangiecta-
sia–mutated (ATM) (Matsuoka et al. 2000). Activated
CHEK2 phosphorylates critical cell-cycle proteins, in-
cluding p53 (MIM 191170), Cdc25C (MIM 157680),
Cdc25A (MIM 116947) and BRCA1 (MIM 113705),
promoting cell-cycle arrest and activation of DNA repair
(Zeng et al. 1998; Chehab et al. 2000; Lee et al. 2000;
Falck et al. 2001).
Previous studies have demonstrated that a protein-
truncating variant in CHEK2, 1100delC, is associated
with an increased risk of breast cancer. This variant lies
within the kinase domain and abrogates kinase func-
tion. The variant was originally identiﬁed by Bell et al.
(1999) in a woman with breast cancer who had a family
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history compatible with Li-Fraumeni syndrome. Mei-
jers-Heijboer et al. (2002) identiﬁed this same variant
in affected women in a large multiple-case family with
breast cancer from the Netherlands that did not show
linkage to BRCA1 or BRCA2 (MIM 600185). Further
analyses demonstrated that this variant was present in
18/1,620 (1.1%) of controls from England, the Neth-
erlands, and the United States but in 55/1,071 (5.1%)
of breast cancer cases from multiple-case families that
did not segregate BRCA1 or BRCA2 mutations, a fre-
quency difference that was highly statistically signiﬁcant
( ). No excess frequency was observedPp .00000003
in cases carrying a BRCA1 or BRCA2 mutation. Hap-
lotype analysis conﬁrmed that all CHEK2*1100delC
mutations derived from a common founder. A similar
association was found in another study based on 1,035
unselected breast cancer cases, 507 breast cancer cases
with a positive family history, and 1,885 controls from
Finland (Vahteristo et al. 2002). The frequencies in fa-
milial breast cancer cases and controls were very simi-
lar to that observed by Meijers-Heijboer et al. (2002)
(4.5% in cases vs. 1.4% in controls; ). Mei-Pp .0002
jers-Heijboer et al. (2002) found an even higher fre-
quency in cases with a family history of male breast
cancer, suggesting an association between CHEK2*
1100delC and male breast cancer, but this association
was not replicated in series of male patients with breast
cancer unselected for family history (Neuhausen et al.
2004).
Two further studies, one based on New York (pre-
dominantly Ashkenazi Jewish) cases and controls and
one conducted in Spain, found no signiﬁcant association
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between CHEK2*1100delC and breast cancer (Ofﬁt et
al. 2003; Osorio et al. 2004). The former study found
the variant in 3/300 (1%) cases (including 192 with a
positive family history), compared with 5/1,665 (0.3%)
controls. The results of this study were therefore com-
patible with an association, betweenCHEK2*1100delC
and breast cancer, of a magnitude similar to that seen
by Meijers-Heijboer et al. (2002) and Vahteristo et al.
(2002); however, given the sample size and the low fre-
quency of the variant, the study had little power to
demonstrate a moderate risk. The latter study included
456 cases (including 400 cases with a family history and
56 cases diagnosed before age 40 years) and 400 con-
trols but found no CHEK2*1100delC carriers among
either cases or controls, indicating a low frequency of
the variant in the Spanish population.
The studies byMeijers-Heijboer et al. (2002) andVaht-
eristo et al. (2002) provide strong evidence that CHEK2*
1100delC is a breast cancer susceptibility allele. Although
the variant was originally identiﬁed in a family with Li-
Fraumeni syndrome (Bell et al. 1999), these studies in-
dicate that CHEK2*1100delC is not a rare allele asso-
ciated with a high lifetime risk of breast cancer but is a
susceptibility allele that is prevalent inWestern European
populations. However, the breast cancer risks associated
with the allele are uncertain. Meijers-Heijboer et al.
(2002) used segregation analysis to estimate that the rel-
ative risk associated with the variant was 1.7 (95% CI
1.32–2.20) in females and 10.28 (95% CI 3.54–29.87)
in males. This analysis, however, effectively assumed that
CHEK2*1100delC multiplies the risks associated with
other susceptibility genes. It does not, therefore, neces-
sarily provide a reliable estimate of the overall relative
risk conferred by CHEK2*1100delC in the absence of a
strong family history. Indeed, the existing studies do not
demonstrate a deﬁnite risk to women without a family
history. Both Meijers-Heijboer et al. (2002) and Vaht-
eristo et al. (2002) studied series of breast cancer cases
unselected for family history, but these series were small,
and the CHEK2*1100delC frequencies did not differ
signiﬁcantly from those in the corresponding control
populations.
To evaluate more thoroughly the association between
CHEK2*1100delC and breast cancer risk at the pop-
ulation level, we have tested the variant in 10 case-
control studies, including ∼11,000 cases and 9,000
controls.
Methods
Data Sets
Subjects were drawn from 10 case-control studies con-
ducted in ﬁve countries (see table 1). To be eligible for
inclusion in the present study, cases were required to be
selected from a series of female invasive breast cancers
with no selection for family history. Most of the studies
made some selection on the basis of age at diagnosis.
Controls were required to be from the same geographical
region. Brief details of the studies are as follows:
1. Anglian Breast Cancer Study (ABC): Cases were
ascertained as part of an ongoing study based on
the East Anglian Cancer Registry (The Anglian
Breast Cancer Study Group 2000). All patients
who received diagnoses before age 55 years since
1991 and who were alive in 1996, together with
all patients who received diagnoses before age 65
years from 1996 to the present, were eligible to
take part. Female controls were randomly selected
from EPIC-cohort, a component of the European
Prospective Investigation into Cancer (EPIC) study
(Day et al. 1999). EPIC is a prospective cohort
study of diet and health being performed in nine
European countries. The EPIC-Norfolk (East An-
glia) cohort comprises ∼25,000 individuals aged
45–74 years. The ethnic background of both cases
and controls was similar, with 195% being white.
2. U.K. National Case-Control Studies (UKNCC):
Cases were ascertained from two population-based
case-control studies conducted in the United King-
dom. The ﬁrst study included 755 women who re-
ceived diagnoses before age 36 years and registered
from 1982 to 1985. The second study included 644
women who received diagnoses at age 36–45 years
and registered from 1998 to 1999. Cases were as-
certained through cancer registries from throughout
Britain in the ﬁrst study and from South Thames,
Oxford, and Yorkshire in the second. Blood samples
from a total of 336 patients from the ﬁrst study and
450 patients from the second study were obtained.
Samples from controls (matched by age and general
practitioner to the cases) were also obtained. For
this study, DNA from a total of 564 cases and 288
controls was available for analysis (Meijers-Heij-
boer et al. 2002).
3. Erasmus Rotterdam Health and the Elderly Study
(ERGO): Cases were from a population-based se-
ries of 439 cases of cancer of any site diagnosed
at ages 55 years and older, ascertained through the
ERGO, together with 460 age-matched controls
(Meijers-Heijboer et al. 2002). The 79 breast can-
cer cases from this study were included in the pres-
ent analysis.
4. PROSPECT: Cases were a consecutive series of pa-
tients with breast cancer, from Rotterdam (np
) and Leiden ( ), who received diag-680 np 473
noses over the period from October 1996 to July
2002. Patients from Rotterdam received diagnoses
before age 70 years, whereas patients from Leiden
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were unselected for age. Controls ( ) werenp 278
random blood donors. Genotyping for this study
was available for 1,066 cases and 265 controls.
5. The Rotterdam Medical Oncology Tumorbank
(RMOT): DNA samples from 1,706 breast tumor
specimens were available for analysis from this
study. The ﬁrst series ( ) was drawn fromnp 503
a consecutive series of unselected cases diagnosed
in the year 1990 (Berns et al. 1992). The second
series ( ) comprises cases that were diag-np 269
nosed before age 40 years, with exclusion of the
early-onset cases from the ﬁrst cohort. The re-
maining cases ( ) were drawn from ongo-np 934
ing studies of prognostic and predictive markers.
The patients originated mainly from the south-
western Netherlands. Controls ( ) werenp 184
spouses of heterozygous cystic ﬁbrosis mutation
carriers from the southwestern Netherlands (Mei-
jers-Heijboer et al. 2002).
6. Helsinki/Tampere: Cases were women with breast
cancer diagnosed over the period 1997–1999 at the
Helsinki ( ) and Tampere ( ) Uni-np 627 np 408
versity Hospitals (Syrjakoski et al. 2000). Controls
( ) were ascertained through the Finnishnp 1,885
Red Cross Blood Transfusion Service (Vahteristo
et al. 2002).
7. Kuopio: Cases ( ) were sampled fromnp 498
women with breast cancer participating in theKuo-
pio Breast Cancer Project (Mitrunen et al. 2001).
Controls ( ) were randomly selected andnp 461
individually matched for age (within 5 years) and
area of residence from the National Population
Register. Blood samples were collected between
April 1990 and December 1995. Genotyping for
this study was available for 464 cases and 447
controls.
8. Heidelberg: Cases were sampled from individuals
participating in a population-based study of breast
cancer, conducted in the state of Baden-Wu¨rttem-
berg in southern Germany. The 706 female cases
aged !51 years at diagnosis were matched with
1,381 controls by age and area of residence (Chang-
Claude et al. 2000). Blood samples for DNA ex-
traction were available for 95% of cases and 82%
of controls. This present studywas based on samples
from 417 cases and 478 controls from the city of
Heidelberg and 187 cases and 172 controls from
Freiberg.
9. Hannover: Cases were women with breast cancer
treated consecutively at the Department of Radi-
ation Oncology of the Medical School, Hannover,
during the years 1996–1999, who were residents
of Lower Saxony. Cases were unselected for age.
Controls were random blood donors from the same
geographical region (Do¨rk et al. 2001).
10. Australian Breast Cancer Case-Control Family
Study (ABCFS): Cases and controls were drawn
from a population-based case-control family study
of breast cancer. Cases were identiﬁed through the
cancer registries in Victoria and New SouthWales.
They includedwomen living in theMelbournemet-
ropolitan area recruited from 1992 through 1999
and women living in the Sydney metropolitan area
recruited from 1993 through 1998. All patients
who received diagnoses before age 40 years and a
random sample of patients aged 40–59 years at
diagnosis were contacted. Controls were identiﬁed
from the electoral roll as living in Melbourne or
Sydney and were chosen so that their age distri-
bution matched that expected of the cases (Hopper
et al. 1999). A total of 1,474 cases and 736 controls
for whom DNA material was available were used
for this study (Spurdle et al. 2002).
Genotyping
For details of the methods used for genotyping
CHEK2*1100delC in each study, see the appendix (on-
line only).
Statistical Methods
Unconditional logistic regression analysis was used to
estimate the odds ratio and 95% CI for breast cancer risk
associated with the CHEK2*1100delC variant. Analyses
were performed with adjustment for study, using the stud-
ies as individual strata, to allow for variation in prevalence
among studies. Further stratiﬁcation by center within in-
dividual studies was also performed. However, this made
no material difference to the estimates, and, for consis-
tency across studies, the former stratiﬁcation was used.
An empirical signiﬁcance level associated with the esti-
mated odds ratio was obtained by performing 108 random
permutations of case-control status of subjects within
strata. The homogeneity of the odds ratio across studies
was assessed using a likelihood-ratio test. The trend in
relative risk by age at diagnosis was assessed by logistic
regression, treating CHEK2*1100delC positivity as the
outcome variable and age at diagnosis as a continuous
covariate.
The absolute age-speciﬁc cumulative risks of breast
cancer in carriers of CHEK2*1100delC were estimated
from the combined estimate of the relative risk across
all studies and the incidence rates in England and Wales
for the period 1988–1990. The proportion of the fa-
milial risk attributable to CHEK2*1100delC was de-
rived using the formula , where lC is thelog (l )/ log (l )C O
relative risk of breast cancer in daughters of cases that
would be expected on the basis of CHEK2*1100delC
alone, and lO is the corresponding familial risk observed
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Table 1
CHEK2*1100delC Genotype Distributions in Cases and Controls, by Study
STUDY POPULATION
CHEK2*1100delC GENOTYPE
DISTRIBUTIONa
Cases Controls
ve/Total % ve/Total %
1. ABC East Anglia, United Kingdom 35/2,886 1.2 20/3,749 .53
2. UKNCCb United Kingdom 7/564 1.3 1/288 .35
3. ERGOb Rotterdam, Netherlands 2/79 2.5 6/460 1.3
4. PROSPECT Southwestern Netherlands 35/1,066 3.3 0/265 …
5. RMOTc Southwestern Netherlands 65/1,706 3.8 3/184 1.6
6. Helsinkid Finland 21/1,035 2.1 26/1,885 1.4
7. Kuopio Finland 13/464 2.9 5/447 1.1
8. Heidelberg Baden Wu¨ttenberg, Germany 2/601 .33 1/650 .15
9. Hannover Lower Saxony, Germany 11/985 1.1 1/401 .25
10. ABCFS Melbourne and Sydney, Australia 10/1,474 .68 1/736 .14
a ve p number who tested positive for CHEK*1100delC.
b Results previously included in Meijers-Heijboer et al. (2002).
c Results for controls previously included in Meijers-Heijboer et al. (2002).
d Results previously included in Vahteristo et al. (2002).
in epidemiological studies. lC was calculated using the
formula , where r is2 2 2 2[pr  q(pr q) ]/[(1 q )r q ]
the estimated relative risk of breast cancer in carriers, p
is the CHEK2*1100delC allele frequency, and qp
. lO was taken to be 1.87, the average relative risk1 p
of breast cancer associated with a positive ﬁrst-degree
family history from the combined analysis reported by
the Collaborative Group on Hormonal Factors in Breast
Cancer (2001).
Results
The prevalences of the CHEK2*1100delC variant in
cases and controls in each study are given in table 1,
and the corresponding estimated odds ratios are pro-
vided in ﬁgure 1. The overall prevalence in controls was
0.71%, but there was substantial variation in carrier
frequency by study ( ; ). The fre-2x p 29.30 P ! .000019
quency was highest in the Finnish studies (combined
frequency 1.3%) and in the Netherlands (0.99%) and
lowest in the Australian (0.14%) and German (com-
bined frequency 0.19%) studies, with an intermediate
frequency in the United Kingdom (0.52%). Although no
controls were positive in the PROSPECT study, the fre-
quency was not signiﬁcantly lower than in the other
Dutch studies.
The overall estimated odds ratio associated with
CHEK2*1100delC, adjusting for center, was 2.34 (95%
CI 1.72–3.20; by simulation). There wasPp .0000001
no evidence of heterogeneity in the odds ratio among
studies ( ) or among countries ( ). In2 2x p 7.75 x p 4.779 4
all 10 studies, the estimated odds ratio is 11, although
the excess risk was only signiﬁcant at the 5% level in
the ABC study and the PROSPECT study.
The prevalence of CHEK2*1100delC was somewhat
greater in women reporting a ﬁrst-degree relative with
breast cancer (26/1,214 [2.1%] vs. 107/7,454 [1.4%])
(OR 1.44; 95% CI 0.93–2.23; ). ComparedPp .1
with controls, the odds ratio associated with CHEK2*
1100delC was 2.23 (95% CI 1.60–3.11) for women
who reported no ﬁrst-degree relatives with breast can-
cer, 3.12 (1.90–5.15) for women who reported one ﬁrst-
degree relative with breast cancer, and 4.17 (1.26–
13.75) in women who reported two or more ﬁrst-degree
relatives with breast cancer.
There was some evidence that the prevalence of
CHEK2*1100delC in cases decreased with age at di-
agnosis ( ). The odds ratio associated withP p .002trend
CHEK2*1100delC was 7.91 (3.95–15.86) for cases di-
agnosed before age 30 years, 2.65 (1.65–4.26) in the
age group 30–39 years, 2.80 (1.90–4.11) in the age
group 40–49 years, 2.13 (1.44–3.15) in the age group
50–59 years, 1.95 (1.23–3.10) in the age group 60–69
years, and 1.82 (1.07–3.09) in the age group70 years.
Sixty-seven of the breast cancer cases genotyped for
CHEK2*1100delC were reported to be carriers of a
deleterious mutation in BRCA1, and 63 were reported
to be carriers of a deleterious mutation in BRCA2 (one
case carried a mutation in both genes). None of the
carriers of BRCA1 or BRCA2 mutations were found
also to carry a CHEK2*1100delC mutation, as com-
pared with the 1.83 that would have been expected on
the basis of the prevalence of CHEK2*1100delC in the
corresponding case series ( ) and the 0.58 thatPp .16
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Figure 1 Estimated odds ratios with 95% CIs for the breast
cancer odds ratios associated with CHEK2*1100delC. The area of
each square is proportional to the variance of the log odds ratio. The
PROSPECT study is not shown individually (but is included in the
combined analysis), since there were no CHEK2*1100delC-positive
controls and, therefore, the estimated odds ratio was inﬁnity.
would have been expected given the prevalence in the
corresponding control series.
Discussion
This study provides strong conﬁrmation that CHEK2*
1100delC is associated with an increased risk of breast
cancer, with the increased risk in carriers of the variant
being approximately twofold. The large majority of the
data (9,182 cases and 6,248 controls) have not been
published previously. The strength of this evidence is
provided not only by the level of statistical signiﬁcance
( ) but also by the consistency across stud-Pp .0000001
ies from ﬁve countries. The estimated odds ratio was 11
for all 10 of the studies, and, although formally signif-
icant only in the largest study (ABC; ) and inPp .003
the PROSPECT study ( ), there was no signif-Pp .001
icant evidence of heterogeneity in the odds ratio across
studies. Of the 10 studies, 6 were based on cases drawn
from population-based cancer registries with popula-
tion-based controls. Only 4 studies used hospital-based
cases and/or blood-donor controls, and exclusion of
these studies made essentially no difference to the results.
Finally, all of the studies are from populations of
Northern European descent that are relatively ethnically
homogeneous. Thus, the observed association is unlikely
to be the result of confounding due to population
stratiﬁcation.
Although it remains formally possible that the asso-
ciation is due to confounding with another variant in
linkage disequilibriumwith it, this also appears unlikely.
Sequencing of the CHEK2 coding regions of 89 familial
breast cancer cases has revealed no other variants in
strong linkage disequilibrium with CHEK2*1100delC
(Schutte et al. 2003).
Although there was no evidence for variation in the
relative risk associated with CHEK2*1100delC among
studies, there was substantial variation in the allele fre-
quency. It is possible that some of this variation was
due to differences in genotyping technology. Analysis of
the CHEK2 gene is problematic as a result of multiple
pseudogene copies. Although all techniques were vali-
dated using positive controls, it is possible that some
positives may have been missed. Since the overall prev-
alence is low, reduced sensitivity is difﬁcult to detect.
Nevertheless, since all positives were reconﬁrmed, the
speciﬁcity of all techniques was high, and, hence, the
relative risk would not be materially affected by tech-
nological artefacts. Some real variation in allele fre-
quency among populations is not unexpected, given that
the allele is relatively rare and, hence, perhaps of rela-
tively recent origin. We found the highest frequency of
CHEK2*1100delC in series from Finland and the Neth-
erlands. The low frequency of CHEK2*1100delC found
by Osorio et al. (2004) in the Spanish population would
be consistent with real frequency variation among pop-
ulations. The rarity of the CHEK2*1100delC may re-
ﬂect some level of selection against the variant, although
this presumably operates through some selective pres-
sure other than breast cancer risk.
Consistent with previous observations, we found only
weak evidence for a decline in the relative risk with age.
The relative risk was higher (7.91) before age 30 years,
but this was based on only 11 CHEK2*1100delC-pos-
itive cases. The absence of any CHEK2*1100delC in
known carriers of BRCA1 and BRCA2 mutations, al-
though based on small numbers and potentially due to
chance, is also consistent with the previous observations
in familial cases and suggests that CHEK2*1100delC
does not confer a comparable increased risk in BRCA1
or BRCA2 mutations, possibly because of functional
redundancy.
The previous evidence for an association between
CHEK2*1100delC and breast cancer was based on a
comparison between the frequency of the variant in
breast cancer cases with a family history of the disease
and that in controls, as well as (to a lesser extent) on
1180 Am. J. Hum. Genet. 74:1175–1182, 2004
linkage of the variant with disease in multiple-case fam-
ilies (Meijers-Heijboer et al. 2002; Vahteristo et al. 2002).
Both studies found a frequency of ∼5% in familial cases,
with the prevalence increasing with the number of af-
fected relatives. Meijers-Heijboer et al. (2002) hypothe-
sized that these data were consistent with a model in
which CHEK2*1100delC multiplied the risks associated
with variants of other susceptibility genes, so that it con-
ferred the same relative risk regardless of the genotypes
at other susceptibility loci. On the basis of this model,
they estimated that CHEK2*1100delC would confer a
relative risk of 1.70 (1.32–2.20). However, since almost
all of the case data were from multiple-case families with
breast cancer, the results might also be consistent with a
model in which CHEK2*1100delC “interacted” more
speciﬁcally with other higher-risk susceptibility genes,
such that the increased risk associated with CHEK2*
1100delC was only manifest in the presence of other
high-risk alleles. If this latter hypothesis were true, the
association between CHEK2*1100delC and breast can-
cer in population studies would be expected to beweaker.
The estimated relative risk from the current study is con-
sistent with (and, in fact, somewhat higher than) the risk
postulated by Meijers-Heijboer et al. (2002) and there-
fore better ﬁts the former, multiplicative model. The in-
creasing prevalence of CHEK2*1100delC in cases with
a family history of the disease in this study, albeit based
on small numbers, is also consistent with such a model.
If we assume a relative risk of 2.34 in CHEK2*1100delC
carriers, the prevalence in cases with one or two affected
relatives would be expected to be 3.7- and 6.0-fold higher
than that in controls, respectively, compared with the
observed 3.12-fold (1.90–5.15) and 4.17-fold (1.26–
13.75) increases. Antoniou et al. (2002) have suggested
that susceptibility to breast cancer in noncarriers of
BRCA1 and BRCA2 mutations may be mainly attrib-
utable to a “polygenic” model, with a large number of
susceptibility alleles, each conferring a small increase in
risk but combining in an approximately multiplicative
fashion. The pattern of risks conferred by CHEK2*
1100delC would appear to be consistent with such a
model. However, it is important to note that, although
the data appear statistically compatible with a simple
multiplicative model, the power to discriminate models
in such studies is relatively poor, and the precise pattern
of combined effects of CHEK2*1100delC and other sus-
ceptibility loci may be more complex. In particular, as
noted above, the combined effects of CHEK2*1100delC,
BRCA1, and BRCA2 are not consistent with a multipli-
cative model. Further evaluation of such interactions will
require the identiﬁcation of further susceptibility genes
and the joint analysis of multiple loci.
If we assume a constant relative risk with age and an
estimated carrier frequency of 0.5% (the observed fre-
quency in the U.K. series), the estimated absolute cu-
mulative risk of breast cancer in carriers of CHEK2*
1100delC would be 13.7% by age 70 years, compared
with 6.1% in noncarriers; on the basis of the age-speciﬁc
relative estimates, the corresponding estimate would be
13.3% by age 70 years. The estimated proportion of
breast cancer cases attributable to CHEK2*1100delC
would be 0.7%, and 0.5% of the excess familial risk
of breast cancer would be attributable to CHEK2*
1100delC. These attributable fractions will, however,
vary according to the population frequency of the var-
iant. It is also possible that other variants in CHEK2
may also contribute to breast cancer susceptibility. Re-
sequencing of familial breast cancer cases has, however,
not identiﬁed any other protein-truncating variants in
CHEK2 nor any other variants clearly associated with
breast cancer (Schutte et al. 2003). Kilpivaara et al. (in
press), in a case-control study based on 1,383 breast
cancer cases and 1,885 controls from Finland, found
some evidence that the variant I157T may also be as-
sociated with breast cancer risk (estimated odds ratio
1.38 [95% CI 1.03–1.83]). However, this variant has
been found to be rare in other populations (Schutte et
al. 2003; A. M. Dunning, P. D. P. Pharoah, D. F. Easton,
and B. A. J. Ponder, unpublished data) and this asso-
ciation has not been replicated. An analysis of two
known common polymorphisms, IVS138insA and
A1013G, in 1,786 cases and 1,828 controls (drawn
from the ABC study), found that neither were associated
with breast cancer risk (Kuschel et al. 2003).
It is interesting to note that the level of statistical sig-
niﬁcance ( ) for the association betweenPp .0000001
CHEK2*1100delC and breast cancer in this study is quite
similar to that achieved in the study by Meijers-Heijboer
et al. (2002). The number of individuals genotyped in
this study was, however, more than sevenfold greater.
This difference illustrates the much greater power to de-
tect associations that can be achieved by using cases en-
riched for family history (Antoniou and Easton 2003).
Conversely, the population-based studies provide a more
robust estimate of the risk associated with the variant.
The relative risk conferred by CHEK2*1100delC is
modest in comparison with that conferred by deleteri-
ous mutations in BRCA1 and BRCA2 and comparable
to some lifestyle risk factors for breast cancer, such as
parity. It is therefore unlikely that predictive testing for
CHEK2*1100delC alone will be generally appropriate
at this stage. However, because the effects of CHEK2*
1100delC and family history may be approximately
multiplicative, CHEK2 carrier status may substantially
alter the absolute risk of breast cancer in women with
a strong positive family history of the disease, and pre-
dictive testing may become useful in this context.
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